Financial

Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of an inducement equity award to a newly hired employee (the “Awardee”). The award was approved by the Company’s Compensation Committee, which is comprised of independent directors, on […]

Madrigal Pharmaceuticals Announces Pricing of Secondary Offering

WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, today announced the pricing of the previously-announced underwritten secondary offering by […]

InspireMD Announces Planned Leadership Transition

Life sciences industry veteran Marvin Slosman appointed Chief Executive Officer   Appointment adds significant medical technology commercialization experience to the InspireMD team TEL AVIV, Israel, Dec. 10, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused […]

Orchestra BioMed™ Secures $20 Million Financing Facility from Silicon Valley Bank

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced that it has entered into a $20 million credit facility agreement with Silicon Valley Bank (SVB), the bank of the world’s most […]

Correvio Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss Brinavess™ For Recent Onset Atrial Fibrillation

NASDAQ: CORV   TSX: CORV VANCOUVER, Dec. 10, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that NASDAQ and the Toronto Stock Exchange (TSX) have halted trading of the Company’s common stock.  The U.S. Food and Drug Administration (FDA)’s Cardiovascular and Renal […]

Quantum Genomics and Biolab Sanus Pharmaceutical Enter into Exclusive Licensing and Collaboration Agreement for Firibastat in Latin America

Biolab Sanus Pharmaceutical to receive an exclusive license to develop and commercialize firibastat for the treatment of arterial hypertension in Latin America PARIS and NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the […]